The eight main blood types are A+, A-, B+, B-, O+, O-, AB+, and AB-. The most common blood type in the United States is O-positive, with around 38 percent of the population having this type of blood. However, blood type O-positive is more common in Latino-Americans than other ethnicities, with around 53 percent of Latino-Americans with this blood type, compared to 47 percent of African Americans and 37 percent of Caucasians. Blood donation The American Red Cross estimates that every two seconds someone in the United States needs blood or platelets, highlighting the importance of blood donation. It was estimated that in 2021, around 6.5 million people in the U.S. donated blood, with around 1.7 million of these people donating for the first time. Those with blood type O-negative are universal blood donors, meaning their blood can be transfused for any blood type. Therefore, this blood type is the most requested by hospitals. However, only about seven percent of the U.S. population has this blood type. Blood transfusion Blood transfusion is a routine procedure that involves adding donated blood to a patient’s body. There are many reasons why a patient may need a blood transfusion, including surgery, cancer treatment, severe injury, or chronic illness. In 2021, there were around 10.76 million blood transfusions in the United States. Most blood transfusions in the United States occur in an inpatient medicine setting, while critical care accounts for the second highest number of transfusions.

The most common blood type among the population in the United States is O-positive. Around 53 percent of the Latino-American population in the U.S. has blood type O-positive, while only around 37 percent of the Caucasian population has this blood type. The second most common blood type in the United States is A-positive. Around 33 percent of the Caucasian population in the United States has A-positive blood type. Blood type O-negative Those with blood type O-negative are universal donors as this type of blood can be used in transfusions for any blood type. O-negative blood type is most common in the U.S. among Caucasian adults. Around eight percent of the Caucasian population has type O-negative blood, while only around one percent of the Asian population has this blood type. Only around seven percent of all adults in the United States have O-negative blood type. Blood Donations The American Red Cross estimates that someone in the United States needs blood every two seconds. However, only around three percent of age-eligible people donate blood yearly. The percentage of adults who donated blood in the United States has not fluctuated much for the past two decades. In 2021, around 15 percent of U.S. adults donated blood, the same share reported in the year 2003.

According to Cognitive Market Research, the global blood group typing market size is USD XX million in 2023 and will expand at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.

The global blood group typing market will expand significantly by 8.8% CAGR between 2024 to 2031.
North America held the major market of more than XX% of the global revenue with a market size of USD XX million in 2023 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Europe accounted for a share of over XX% of the global market size of USD XX million.
Asia Pacific held a market of around XX% of the global revenue with a market size of USD XX million in 2023 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Latin America's market will have more than XX% of the global revenue with a market size of USD XX million in 2023 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2023 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The blood group typing industry is set to rise due to increased blood group ownership rates, rising awareness regarding blood group health, accelerated R&D in the blood group typing industry, and the rise of E-commerce. Increasing online retail channels further bolster demand, while cultural significance and investment appeal contribute to its enduring popularity.
The blood group typing market is driven by rising awareness regarding blood group health, accelerated R&D in the blood group typing industry, and the rise of E-commerce.
Antibody Screenings are anticipated to form the majority of blood group owners in the years to come.

Current Scenario of the Blood Group Typing Market

Key Drivers of the Blood Group Typing Market

The growing incidence of chronic illnesses and the increase in surgical operations necessitates the need for blood donations.

The demand for blood has grown as chronic diseases and the surgical procedures necessary to treat them have become more common. Blood transfusions are typically necessary for patients with chronic illnesses to manage their symptoms, and large volumes of blood are required for surgical procedures, particularly major surgeries, to ensure safe and effective results. As a result, the need for blood has steadily increased within the healthcare system, which has led to a rise in blood donation rates. The market is anticipated to benefit from this. To treat patients with chronic illnesses and those having difficult surgical operations, the American National Red Cross (2023) estimates that every day, over 29,000 units of red blood cells are required in US hospitals and emergency rooms. For instance, according to the National Center for Biotechnology Information, the number of people 50 years of age and older who have at least one chronic illness is predicted to rise from 71.522 million in 2020 to 142.66 million in 2050, a 99.5% increase.

Source- https://pubmed.ncbi.nlm.nih.gov/36711415/#:~:text=Of%20the%20population%2050%20years,to%2014.968%20million%20in%202050.

Blood group typing is a necessary test that establishes the Rh factor and the level of blood compatibility between the donor and the recipient prior to blood transfusions. Thus, the need for blood donations is a result of the rising prevalence of chronic illnesses and the rise in surgical procedures.

Blood Donation rates have necessitated the need for Blood Group Typing-

Global blood donation rates have significantly increased over time. The need for transfusion procedures such as blood type detection and cross-matching has surged due to a rise in voluntary blood donations. The National Health Service Blood and Transplant (NHSBT) receives over 1.5 million voluntary blood donations annually, which are processed by the government before being given to hospitals and patients in need, according to an article published by the European Blood Alliance (EBA) (2019–2022).

Source- https://www.nhsbt.nhs.uk/who-we-are/a-history-of-donation-transfusion-and-transplantation/

NHSBT supplies hospitals in England with a secure and dependable supply of blood components, diagnostic services, and stem cell treatments. To do this, it depends on...

ABO Blood Type Test Kit Market Outlook

The global ABO blood type test kit market size was valued at USD 780 million in 2023 and is projected to reach USD 1.2 billion by 2032, growing at a CAGR of 4.8% during the forecast period. The market for ABO blood type test kits is experiencing robust growth primarily driven by increasing demand for blood transfusion services, advancements in diagnostic technologies, and the rising prevalence of chronic diseases necessitating blood type testing. These factors contribute significantly to the market's expansion and its optimistic outlook.

One of the primary growth factors for the ABO blood type test kit market is the increasing number of surgical procedures and trauma cases worldwide, which demand immediate and accurate blood typing. Additionally, the growing awareness about the importance of blood typing in organ transplantation and prenatal testing further propels the market. The surge in blood donation drives and the need for efficient blood bank management systems, which rely heavily on accurate blood type testing, also significantly contribute to market growth.

Technological advancements in diagnostic techniques, such as the development of rapid test kits that offer quick and reliable results, are another critical driver of market expansion. These innovations have made blood typing more accessible and convenient, particularly in remote and underserved areas. The rising adoption of point-of-care testing, which allows for blood type determination outside traditional laboratory settings, is also enhancing the market's growth prospects.

The increasing prevalence of chronic diseases, such as cancer and kidney disorders, which often require regular blood transfusions, is a significant factor fueling the demand for ABO blood type test kits. Moreover, the aging global population, which is more susceptible to various medical conditions requiring blood transfusions, contributes to the sustained demand for these kits. Public health initiatives and government policies promoting regular health check-ups and blood donation are also playing a crucial role in driving the market forward.

From a regional perspective, North America holds a dominant position in the ABO blood type test kit market due to its well-established healthcare infrastructure, high awareness levels, and significant investments in healthcare technologies. Europe follows closely, driven by similar factors along with a strong focus on research and development. The Asia Pacific region is expected to witness the fastest growth, attributed to its large population base, increasing healthcare expenditures, and rising awareness about blood-related health issues. Other regions, including Latin America and the Middle East & Africa, are also showing promising growth potential due to improving healthcare facilities and increasing government initiatives.

Product Type Analysis

The ABO blood type test kit market is segmented by product type into rapid test kits and laboratory test kits. Rapid test kits are designed for quick and efficient blood typing, providing results in a matter of minutes. These kits are particularly useful in emergency situations, field settings, and for point-of-care testing. The demand for rapid test kits is driven by their ease of use, minimal training requirements, and the ability to deliver immediate results, making them highly suitable for use in various non-laboratory settings.

Laboratory test kits, on the other hand, are designed for use in clinical laboratories and provide highly accurate and reliable results. These kits are typically used in hospitals, diagnostic laboratories, and blood banks where precision is crucial. The demand for laboratory test kits is driven by the increasing number of diagnostic procedures and the need for accurate blood type determination in critical medical situations. These kits often employ advanced technologies such as gel cards and microplates, contributing to their high accuracy and reliability.

The rapid test kits segment is expected to witness significant growth during the forecast period due to the increasing adoption of point-of-care testing and the rising need for quick and efficient blood type determination in emergency and remote settings. The convenience and speed offered by rapid test kits are making them increasingly popular among healthcare providers and individual consumers alike. Additionally, advancements in rapid testing technologies are further enhancing the accuracy and reliability of these kits, contributing to their growing demand.

Snapshot img

Blood-Grouping Reagents Market Size 2025-2029

The blood-grouping reagents market size is forecast to increase by USD 611.8 million, at a CAGR of 8.8% between 2024 and 2029.

The market is driven by the increasing prevalence of chronic disorders necessitating frequent blood transfusions. The rising incidence of diseases such as cancer and thalassemia, among others, fuels the demand for blood-grouping reagents. Moreover, advancements in diagnostic devices, including automation of blood grouping systems and point-of-care devices, are streamlining the blood-grouping process, enhancing accuracy, and reducing turnaround time. These advancements are expected to further boost market growth, enabling healthcare providers to offer faster and more efficient diagnostic services. However, the risks associated with blood transfusion, including transfusion reactions and disease transmission, pose significant challenges.
Ensuring the safety and efficacy of blood-grouping reagents is crucial to mitigating these risks and maintaining patient trust. Companies in this market must prioritize innovation and regulatory compliance to address these challenges and capitalize on the growing demand for blood-grouping reagents.

What will be the Size of the Blood-Grouping Reagents Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market is characterized by its continuous evolution, driven by the need for enhanced pre-transfusion and post-transfusion safety in the transfusion medicine sector. Reagents play a crucial role in ensuring quality assurance during various stages of blood transfusion, from specimen collection to antibody identification and lot number tracking. Pre-transfusion testing in hospital laboratories relies on high-throughput screening using automated immunoassay analyzers and flow cytometry for rapid and accurate blood grouping. Reagents for ABO grouping and Rh typing are essential in this process, requiring strict regulatory compliance and shelf life management. Post-transfusion testing is equally important, with polyclonal antibodies and monoclonal antibodies used for antibody screening and identification.

Quality control measures, including expiration dates, lot numbers, and reagent stability, are essential to minimize adverse events and maintain transfusion safety. The market for blood grouping reagents also extends to emergency medicine and point-of-care testing (POCT), where microplate technology and rapid testing methods enable quick and accurate results. Specimen preparation and plasma antigens are critical components in the overall process, ensuring accurate and reliable testing outcomes. Clinical trials and ongoing research continue to unfold new applications for blood grouping reagents, including advances in antibody titers, rh typing, and regulatory compliance. The market's dynamic nature underscores the importance of continuous innovation and quality control in the transfusion medicine sector.

How is this Blood-Grouping Reagents Industry segmented?

The blood-grouping reagents industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Hospitals and blood banks
  Clinical laboratories
  Academic and research institutes


Technique

  PCR-based and microarray techniques
  Assay-based techniques
  Massively parallel sequencing techniques
  Serology


Product

  Anti-sera reagents
  Red blood cell reagents
  Blood bank saline
  Others


Test Type

  Blood Grouping & Phenotyping
  Antibody Screening
  Cross-matching Tests
  Coombs Tests
  Antigen Typing
  Antibody Identification


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  South America

    Argentina
    Brazil


  Middle East and Africa

    UAE


  Rest of World (ROW)

By End-user Insights

The hospitals and blood banks segment is estimated to witness significant growth during the forecast period.

The market is significantly driven by the hospitals and blood banks segment due to the high utilization of these reagents for ensuring blood transfusion safety and quality assurance. The increasing number of hospitalizations for cancer treatment, chronic conditions, and emergency cases such as road accidents necessitates the extensive use of blood-grouping reagents in hospitals and blood banks. In emergency departments, these reagents play a crucial role in diagnosis, triage, and determining the need for immediate therapy, which must be carried out within a limited timeframe. Blood-grouping reagents find extensive application in

ABO Blood Group Reagent Market Outlook

The global ABO blood group reagent market size is projected to witness significant growth from $820 million in 2023 to approximately $1.4 billion by 2032, with a compound annual growth rate (CAGR) of 6.2%. The primary growth drivers of this market include the rising prevalence of chronic diseases, increased demand for blood transfusions, and advancements in diagnostic technologies. As healthcare systems worldwide continue to improve and expand, the need for accurate blood typing and cross-matching becomes critical, further driving the market's expansion.

One of the pivotal factors driving the growth of the ABO blood group reagent market is the increasing incidence of chronic diseases and trauma cases requiring blood transfusions. With the aging global population, conditions such as cancer, cardiovascular diseases, and orthopedic surgeries are becoming more prevalent, necessitating frequent blood transfusions. This increases the demand for reliable ABO blood group reagents, which are essential for ensuring patient safety during transfusions. Additionally, increased awareness about blood donation and the safety of blood transfusions is contributing to the market's growth.

Advancements in diagnostic technologies and automated blood typing systems are also propelling the ABO blood group reagent market forward. Modern diagnostic laboratories and blood banks are adopting automated systems that offer high precision and efficiency in blood typing and cross-matching. These advancements reduce human errors, enhance throughput, and improve the overall quality of diagnostic services. The integration of advanced technologies such as artificial intelligence and machine learning in blood group typing is further expected to open new avenues for market growth.

Government initiatives and regulations promoting safe blood transfusion practices are another critical factor contributing to market growth. Stringent guidelines and protocols established by health authorities such as the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) ensure the implementation of reliable and accurate blood typing and cross-matching procedures. These regulations mandate the use of high-quality reagents, thus driving the demand for ABO blood group reagents.

The regional outlook of the ABO blood group reagent market highlights significant growth potential in various parts of the world. North America and Europe are anticipated to dominate the market due to advanced healthcare infrastructure, high healthcare expenditure, and the presence of key market players. Asia Pacific is expected to witness the highest growth rate, driven by an expanding healthcare sector, increasing awareness about blood donation, and supportive government policies. Latin America and the Middle East & Africa regions also present growth opportunities due to improving healthcare access and rising investment in healthcare infrastructure.

Product Type Analysis

The ABO blood group reagent market is segmented by product type into Anti-A Reagents, Anti-B Reagents, Anti-AB Reagents, Anti-D Reagents, and Others. Anti-A reagents hold a prominent position in the market due to their critical role in determining the presence of A antigens in blood samples. These reagents are crucial for ensuring compatibility in blood transfusions and organ transplants. The increasing demand for accurate blood typing in hospitals and diagnostic laboratories is driving the growth of the Anti-A reagents segment.

Anti-B reagents are also witnessing substantial demand as they are essential for detecting B antigens in blood samples. Accurate determination of B antigens is vital for preventing adverse reactions during blood transfusions. The rising prevalence of conditions requiring blood transfusions, such as anemia and trauma, is contributing to the growth of the Anti-B reagents segment. Moreover, advancements in reagent formulations are enhancing the sensitivity and specificity of Anti-B reagents, further boosting their market adoption.

The Anti-AB reagents segment is gaining traction due to its importance in identifying AB blood group individuals. These reagents play a crucial role in blood typing, especially in emergency situations where rapid and accurate identification of blood groups is necessary. The increasing number of surgeries and medical procedures requiring

The global ABO blood typing test kit market is experiencing robust growth, driven by rising prevalence of blood transfusions, increasing incidence of blood-related disorders, and expanding diagnostic testing capabilities in both developed and developing nations. The market, currently estimated at $1.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching a value exceeding $2.5 billion by the end of the forecast period. This expansion is fueled by technological advancements leading to faster, more accurate, and automated testing methods. The increasing adoption of point-of-care testing (POCT) devices contributes significantly to market growth, allowing for rapid blood type determination in various settings, including emergency rooms and remote areas. Furthermore, stringent regulatory frameworks promoting blood safety and the growing awareness of the importance of accurate blood typing before transfusions are key market drivers. The market is segmented by application (hospital, clinic) and type of test kit (positive stereotype, anti-stereotype), with hospitals currently dominating the application segment due to higher testing volumes. Geographic growth is expected to be fairly evenly distributed across regions, with North America and Europe maintaining substantial market shares due to established healthcare infrastructure and high healthcare expenditure. However, rapidly developing economies in Asia-Pacific, particularly China and India, are poised for significant market expansion, driven by growing healthcare investments and increasing adoption of advanced diagnostic technologies. Competition is moderate, with several key players vying for market share. The market faces challenges including the high cost of advanced testing kits and the potential for errors in manual testing procedures. However, ongoing research and development efforts are focused on mitigating these challenges through the introduction of cost-effective and highly accurate automated systems. The prevalence of infectious diseases also presents a constraint, as meticulous safety measures are essential during blood typing procedures. Despite these challenges, the long-term outlook for the ABO blood typing test kit market remains positive, propelled by sustained demand for accurate and rapid blood typing, expanding healthcare infrastructure globally, and the continuous development of innovative testing technologies. The market's growth trajectory underscores the critical role of accurate blood typing in ensuring safe and effective blood transfusions and overall patient care.

The global ABO blood group reagent market is experiencing steady growth, projected to reach a market size of $1.2 Billion by 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 5%. This growth is driven by several key factors, including the rising prevalence of blood-related diseases and increasing demand for accurate and reliable blood typing in hospitals and blood banks worldwide. Advancements in reagent technology, leading to improved accuracy and efficiency, further contribute to market expansion. The positive identification segment dominates the market due to its widespread use in routine blood testing procedures. However, the reverse identification segment is also witnessing substantial growth, driven by the increasing need for confirmatory testing and improved diagnostic accuracy in complex cases. Geographic distribution reveals strong market presence in North America and Europe, driven by well-established healthcare infrastructure and higher adoption rates of advanced technologies. However, the Asia-Pacific region is anticipated to show significant growth potential in the forecast period (2025-2033), fueled by increasing healthcare spending and rising awareness regarding blood safety. While the market faces certain restraints such as stringent regulatory approvals and the availability of cost-effective alternatives, the overall positive outlook remains driven by consistent demand for accurate and efficient blood typing solutions. The market segmentation by application reveals that hospitals and blood banks are the largest consumers of ABO blood group reagents, reflecting their critical role in ensuring blood safety and transfusion compatibility. The research segment is also experiencing growth as research institutions increasingly use these reagents in various studies and developments related to blood groups. Key players in the market, such as CE-Immundiagnostika GmbH, Dominion Biologicals Limited, and SHPBC, are focused on product innovation and strategic partnerships to maintain market competitiveness. The market is further shaped by regional differences in healthcare infrastructure, regulatory landscape, and disease prevalence, impacting the regional distribution of market share. Future growth is expected to be influenced by technological advancements, evolving regulatory frameworks, and increased investment in healthcare infrastructure across emerging economies.

The global ABO blood type test kit market is experiencing robust growth, driven by the increasing prevalence of blood transfusions and the rising incidence of blood-related diseases. The market size in 2025 is estimated at $1.5 billion, exhibiting a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This growth is fueled by several factors, including advancements in testing technologies leading to faster and more accurate results, increasing demand for point-of-care testing, and the growing adoption of automated blood typing systems in hospitals and clinics. The market is segmented by test type (positive stereotype, anti-stereotype) and application (hospital, clinic), with hospitals currently holding the largest market share due to higher testing volumes and advanced infrastructure. Geographic expansion, particularly in emerging economies with rising healthcare expenditure and increasing awareness of blood safety, is also significantly contributing to market expansion. Furthermore, the development of innovative kits, including those incorporating molecular diagnostic techniques for enhanced sensitivity and specificity, will further stimulate market growth during the forecast period. While the market faces some restraints, such as stringent regulatory approvals for new test kits and the potential for price competition among manufacturers, the overall growth trajectory remains positive. The increasing adoption of universal blood donor programs and rising investments in research and development aimed at improving the efficiency and accuracy of blood typing are anticipated to offset these challenges. The dominance of key players like DiaMed GmbH and Ortho-Clinical Diagnostics is expected to continue, although smaller companies specializing in niche technologies or geographic regions are likely to gain market share. Continued innovation and strategic partnerships are crucial for players to maintain a competitive edge in this dynamic and expanding market.

• The global industry was valued at US$ 2.6 Bn in 2022
• It is estimated to grow at a CAGR of 8.8% from 2023 to 2031 and reach US$ 5.5 Bn by the end of 2031

Market Introduction

Regional Outlook

Blood Group Typing Market Snapshot

The global blood group typing market is experiencing robust growth, driven by the increasing prevalence of blood transfusions and the rising demand for accurate and rapid blood typing methods. Technological advancements, such as the adoption of automated and high-throughput systems, are significantly improving the efficiency and accuracy of blood typing procedures, leading to faster turnaround times and reduced errors. Furthermore, the growing prevalence of chronic diseases requiring frequent blood transfusions and the increasing number of surgical procedures are contributing to market expansion. The market is segmented by type (manual, automated) and application (blood banks, hospitals, research). The automated segment is witnessing rapid growth due to its advantages in speed, accuracy, and efficiency. Hospitals and blood banks constitute the largest application segments, driven by their high volume of blood typing needs. Key players such as Agena Bioscience, Bio-Rad Laboratories, Danaher, Merck KGaA, and Ortho Clinical Diagnostics are strategically investing in research and development, mergers and acquisitions, and geographical expansion to solidify their market positions. This competitive landscape is fostering innovation and leading to the development of advanced blood typing technologies. The market's geographical distribution demonstrates significant regional variations. North America and Europe currently hold the largest market shares, attributed to well-established healthcare infrastructure, high adoption rates of advanced technologies, and increasing healthcare expenditure. However, developing economies in Asia-Pacific and the Middle East & Africa are exhibiting promising growth potential due to rising healthcare awareness, improving healthcare infrastructure, and increasing government initiatives aimed at enhancing healthcare services. While the market faces challenges such as stringent regulatory requirements and high costs associated with advanced technologies, the overall growth trajectory remains positive, fueled by unmet needs for efficient and precise blood typing solutions. We project sustained market expansion over the forecast period, driven by continued technological innovation and increasing healthcare demands globally.

The global blood type special centrifuge market is poised for significant growth, driven by increasing demand for accurate and efficient blood component separation in hospitals and blood banks. Technological advancements leading to higher-speed, more precise centrifuges with improved safety features are key drivers. The rising prevalence of blood-related disorders and the growing need for blood transfusions globally fuel market expansion. Furthermore, the increasing adoption of automation and sophisticated data management systems in blood banks is streamlining operations and improving efficiency, thereby boosting demand for advanced centrifuges. The market is segmented by application (hospital, blood center, other) and type (refrigerated, non-refrigerated). Hospitals currently hold the largest market share due to their high volume of blood processing needs. However, the blood center segment is expected to witness substantial growth fueled by increasing investment in infrastructure and technological upgrades within these facilities. The non-refrigerated segment is projected to grow at a faster rate due to its cost-effectiveness and ease of use, particularly in resource-constrained settings. Geographic expansion is another key aspect. North America and Europe currently dominate, but rapidly developing economies in Asia-Pacific, particularly China and India, present significant opportunities. Competitive landscape is characterized by established players like Meditech, Thomas Scientific, Grifols, and newer entrants, spurring innovation and enhancing product offerings. Challenges for market expansion include the high initial investment costs associated with advanced centrifuge systems and the stringent regulatory requirements surrounding medical devices. However, these challenges are being mitigated by technological advancements reducing costs and by manufacturers focusing on regulatory compliance. The forecast period (2025-2033) anticipates continued market expansion, driven by factors including increasing healthcare spending, growing awareness of blood safety, and the continuing development of innovative centrifugation technologies. This growth will be further propelled by the expansion of blood banks and hospitals, especially in emerging markets, and the growing focus on personalized medicine, necessitating more precise blood component separation techniques. The market is projected to witness a healthy CAGR, outpacing the general medical equipment market growth rate.

In 2023, there were 12,983 people in the United States who had hemophilia A and around 4,195 people were diagnosed with hemophilia B. This statistic displays the number of people in the U.S. diagnosed with a blood disorder by disorder type, as of 2023.

Blood Type Special Centrifuge Market Outlook

The global blood type special centrifuge market size was valued at approximately USD 1.2 billion in 2023 and is projected to reach nearly USD 2.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This significant growth is driven by an increasing demand for precise blood component separation, rising incidences of blood disorders, and advancing healthcare infrastructure globally.

A major growth factor for the blood type special centrifuge market is the escalating prevalence of blood-related disorders and diseases. Conditions such as anemia, leukemia, and other hematological disorders necessitate the use of specialized centrifuges for accurate diagnosis and treatment. Additionally, the rising number of surgical procedures and the subsequent need for blood transfusions emphasize the importance of efficient blood separation techniques, further driving market demand. Furthermore, advancements in medical technology are enabling the development of more sophisticated and efficient centrifuges, which enhances their adoption in various healthcare settings.

Another critical growth factor is the expanding healthcare infrastructure, particularly in developing regions. Countries in Asia Pacific and Latin America are investing substantially in healthcare facilities and diagnostic laboratories, which in turn increases the demand for advanced medical equipment, including blood type special centrifuges. Additionally, government initiatives and funding aimed at improving healthcare access and quality are positively impacting market growth. For instance, numerous national health programs are focusing on better management of blood banks and transfusion services, which rely heavily on effective centrifugation processes.

The increased focus on research and development in the medical field is also a significant driver of market growth. Research laboratories and academic institutions are increasingly utilizing blood type special centrifuges for various analytical and experimental purposes. The rise in funding for medical research and the growing emphasis on personalized medicine are further contributing to the increasing demand for specialized centrifuges. Moreover, collaborations between universities and commercial entities are fostering innovation in centrifuge technology, leading to the introduction of advanced products in the market.

From a regional perspective, North America holds a substantial share of the blood type special centrifuge market, owing to its well-established healthcare infrastructure, high healthcare spending, and robust presence of key market players. Europe also represents a significant market share, driven by advanced healthcare facilities and increasing focus on research activities. The Asia Pacific region, however, is anticipated to witness the highest growth rate during the forecast period, driven by rapid healthcare advancements and increasing governmental support. This regional growth outlook highlights the global nature of the market's expansion and the diverse factors influencing it.

Product Type Analysis

The blood type special centrifuge market is segmented by product type, which includes benchtop centrifuges, floor-standing centrifuges, high-speed centrifuges, and low-speed centrifuges. Benchtop centrifuges are widely used in various healthcare and research settings due to their compact size and versatility. These centrifuges are particularly popular in smaller laboratories and clinics where space is a constraint. Their ease of use and affordability make them an attractive option for many facilities looking to enhance their diagnostic capabilities without significant financial investment.

Floor-standing centrifuges, on the other hand, are preferred in larger medical and research institutions that require higher capacity and performance. These centrifuges are designed to handle larger volumes of samples and offer superior speed and efficiency compared to benchtop models. The advancements in automation and digital integration in floor-standing centrifuges are driving their adoption in settings where high throughput and precision are critical. Additionally, these centrifuges are often equipped with advanced safety features, making them suitable for handling infectious or hazardous samples.

High-speed centrifuges are another key segment in the market, primarily used for applications requiring rapid separation of blood components. These centrifuges are capable of achieving very high rotational speeds, which significantly

Snapshot img

Blood Market Size 2025-2029

The blood market size is forecast to increase by USD 2.6 billion, at a CAGR of 5.7% between 2024 and 2029.

The market is characterized by significant growth drivers and trends, as well as notable challenges. Moreover, the rising awareness about blood donation is fostering a culture of giving, leading to an increase in voluntary blood donations. Due to limited disposable income and underdeveloped healthcare ecosystems, these regions exhibit a low demand for healthcare services and advanced treatment methods, including blood transfusions. However, the market faces challenges in the form of inadequate blood storage and transfusion facilities, particularly in rural areas.
Companies operating in this market must address this challenge by investing in innovative solutions for blood storage and transportation, ensuring a reliable and efficient blood supply chain. By focusing on these growth drivers and addressing the challenges, market participants can capitalize on the opportunities presented in the market and contribute to saving lives. Blood preservation techniques, such as plasma fractionation, component separation, and cryopreservation, have significantly extended the shelf life of blood products.

What will be the Size of the Blood Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in technology and research across various sectors. Blood utilization spans from diagnostic testing to therapeutic applications, with blood testing playing a crucial role in identifying bloodborne pathogens, monitoring blood chemistry, and diagnosing blood diseases. Blood therapeutics, including coagulation factors, platelet count correction, and artificial blood, offer innovative solutions for managing blood disorders and supporting surgical procedures. Blood culture systems and blood safety standards ensure the integrity of blood samples during collection, storage, and transportation. Blood lipid profile analysis provides valuable insights into cardiovascular health, while blood viscosity and oxygen saturation measurements contribute to understanding blood flow dynamics.

Blood analysis techniques, such as proteomics, immunochemistry, and metabolomics, offer a deeper understanding of blood composition and its role in overall health. Hematology analyzers facilitate accurate blood component analysis, while blood pressure monitoring and blood gas analysis provide essential information for patient care. Blood donation campaigns and blood inventory management systems ensure a steady blood supply, addressing the ongoing demand for blood products. Blood preservation and component separation techniques extend the shelf life and utility of blood components, while blood waste reduction strategies minimize waste and optimize resource utilization. Blood research and development continue to uncover new applications for blood and its components, including blood substitutes, nanotechnology, and genomics.

The market's continuous dynamism underscores the importance of ongoing innovation and collaboration to meet the evolving needs of healthcare professionals and patients alike.

How is this Blood Industry segmented?

The blood industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  WBC and P
  Blood screening products
  Blood typing products
  Source plasma collection


End-user

  Hospitals
  Ambulatory surgical centers (ASCs)
  Others


Application

  Therapeutic
  Diagnostic
  Research and development


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Product Insights

The WBC and P segment is estimated to witness significant growth during the forecast period. The market is witnessing significant growth due to the increasing demand for various blood products and services. Whole blood, which is the unaltered blood drawn from donors, is in high demand for surgical procedures, blood transfusions, and trauma cases. Trauma is a leading cause of death worldwide, with over 5 million fatalities and 1 billion people requiring medical attention each year. Plasma, a component of blood that is separated from whole blood through fractionation, is essential for producing therapeutic proteins and immunoglobulins. Bloodborne pathogens, such as HIV and Hepatitis B and C, pose a significant risk during blood collection, storage, and transfusion.

Strict safety standards and regulations ensure the safety of the blood supply chai

The global blood bank market, valued at $32.03 billion in 2025, is projected to experience robust growth, driven by a rising global population, increasing prevalence of chronic diseases requiring blood transfusions (e.g., cancer, thalassemia), and advancements in blood storage and processing technologies. The increasing demand for safe and readily available blood products, particularly in developing nations, is a significant growth catalyst. Furthermore, growing awareness regarding blood donation and government initiatives promoting blood donation campaigns are contributing to market expansion. Technological advancements such as automated blood component separation systems and improved blood screening techniques enhance efficiency and safety, further fueling market growth. However, challenges remain, including the limited availability of volunteer donors in certain regions, stringent regulatory frameworks governing blood collection and processing, and the potential risk of blood-borne diseases. Segmentation reveals that hospitals are the largest consumers of blood products, followed by laboratories and blood centers. Whole blood currently holds the largest market share among blood product types, though the demand for specialized components like platelets and plasma is growing rapidly due to their critical roles in various medical treatments. The market's geographic distribution reflects varying healthcare infrastructure and donation rates across regions. North America, particularly the United States, dominates the market due to advanced healthcare facilities and high per capita blood donation rates. Europe follows as a significant market, while Asia-Pacific is expected to witness rapid growth in the coming years driven by rising disposable income and increasing healthcare expenditure. Competition among key players, including both large national blood banks and smaller regional players, is intense, marked by investments in R&D, strategic partnerships, and expansion into new markets. The forecast period (2025-2033) anticipates a sustained CAGR of 6.5%, reflecting the continued demand for blood products and ongoing efforts to improve blood bank infrastructure and processes globally. This growth will likely be influenced by factors such as technological innovations, expanding healthcare infrastructure, and evolving public health initiatives.

The global blood grouping and phenotyping reagents market is experiencing steady growth, driven by factors such as the increasing prevalence of blood-related disorders, rising demand for blood transfusions, and advancements in diagnostic technologies. The market size in 2025 is estimated at $2.5 billion, with a compound annual growth rate (CAGR) of 5% projected from 2025 to 2033. This growth is fueled by several key trends, including the increasing adoption of automated blood typing systems in hospitals and blood banks, the development of more accurate and rapid testing methods, and the rising focus on personalized medicine. The hospital segment currently holds the largest market share due to the high volume of blood transfusions performed in these settings. However, the R&D segment is expected to witness significant growth over the forecast period, driven by the increasing demand for innovative blood grouping and phenotyping technologies for research purposes. While the market faces challenges such as stringent regulatory approvals and high costs associated with reagent development, the overall growth trajectory remains positive due to the aforementioned drivers. The competitive landscape is characterized by the presence of both large multinational corporations and smaller specialized companies, leading to innovation and market diversification. Geographic segmentation reveals that North America currently dominates the market, followed by Europe, attributed to well-established healthcare infrastructure and high healthcare expenditure in these regions. However, emerging economies in Asia-Pacific, particularly India and China, are projected to witness substantial growth due to the rising prevalence of blood-related diseases and increasing investments in healthcare infrastructure. The market segmentation by reagent type reveals comparable market shares for blood phenotyping and blood grouping reagents, reflecting the significance of both methodologies in blood transfusion practices and research. Continued technological advancements, coupled with rising healthcare spending and improving diagnostic capabilities, will continue to drive substantial market expansion over the next decade.

Snapshot img

Venous Blood Collection Market Size 2024-2028

The venous blood collection market size is forecast to increase by USD 470.6 million, at a CAGR of 4.5% between 2023 and 2028. The growth of the market is driven by several crucial factors. The increasing prevalence of cardiovascular diseases (CVDs) heightens the demand for advanced diagnostic and therapeutic devices designed to manage and treat heart conditions. Additionally, the increasing incidence of trauma and accidents leads to a greater need for emergency medical equipment and surgical interventions. This trend is further supported by the rising number of surgical procedures globally, which requires a wide range of medical devices for various types of surgeries. These factors collectively contribute to market expansion by driving innovation and investment in medical technologies that address urgent healthcare needs and enhance patient outcomes worldwide.

What will be the Size of the Market During the Forecast Period?

For More Highlights About this Report, Request Free Sample

Market Dynamic and Customer Landscape

The market is witnessing significant growth due to the increasing prevalence of infectious diseases such as hepatitis B, hepatitis C, human immunodeficiency virus (HIV), malaria, and blood cancer. Hospital and Clinics, Blood Donation Center, Diagnostic Center, and Independent Laboratories are the major end-users of venous blood collection tubes and holders. The market is driven by the rising number of road accidents leading to trauma cases and the need for immediate blood transfusion. Laboratory hematologists play a crucial role in the collection and analysis of venous blood samples. The market is segmented based on the type of tubes and holders, including plain, EDTA, heparin, and other types. The market is also expected to grow due to the development of vaccine candidates and molecular diagnostic tests using venous blood samples. Product contamination is a major challenge in the market, and stringent regulations are being implemented to ensure the safety and quality of blood collection tubes and holders. Hydroxychloroquine and other molecules are used in the production of blood collection tubes to prevent contamination and ensure the stability of the samples. The aging population is another factor driving the growth of the market due to the increasing prevalence of chronic diseases and the need for regular monitoring and diagnosis.

Key Market Driver

Increasing prevalence of CVDs is notably driving market growth. Venous blood collection plays a crucial role in diagnosing various chronic and infectious illness conditions, including syphilis, brucellosis, and lifestyle-related diseases, such as cancer and cardiovascular diseases. The global prevalence of these diseases is on the rise, with the World Health Organization reporting an estimated 19.3 million new cancer cases in 2020. Furthermore, the incidence of respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, and lung cancer, is increasing globally. This growing health concern necessitates an increase in diagnostic tests, leading to a higher demand for venous blood collection.

Additionally, the aging population, particularly the geriatric population, requires frequent blood tests due to the higher prevalence of diseases in this demographic. Public-private funding and healthcare policies are also driving the growth of the market, with investments in liquid biopsy tests, vaccine candidates, and molecular-based diagnostics. Surgical procedures and blood donation also contribute to the demand for venous blood collection. Tubes and holders are essential components of the venous blood collection process, ensuring the accuracy and safety of the tests. Hydroxychloroquine and other medications may also require venous blood collection for monitoring and dosage adjustments. Thus, such factors are driving the growth of the market during the forecast period.

Key Market Trends

Growing number of strategic developments is the key trend in the market. The market has witnessed an increasing number of new product launches to cater to the growing demand for advanced diagnostic tests. In February 2022, the Food and Drug Administration (FDA) granted regulatory approval to Roche's Foundation Medicine for a circulatory tumor DNA (CTDNA) assay in plasma, making it the latest FDA breakthrough designation. This test, which identifies molecular residual disease (MRD) in primary cancer patients after curative treatment, is crucial as certain medications eradicate tumors but leave residual illness. The MRD status can help determine if additional therapy is necessary and the risk of recurrence.

Additionally, the market is witnessing significant growth due to the rising prevalence of lifestyle-related diseases, such as diabetes and cardiovascular diseases, in the aging population. Public-private funding and healthcare policies are a